Drug Profile
Paclitaxel-eluting balloon catheter - Cardionovum
Alternative Names: LegflowDCB; Paclitaxel-eluting coronary PTCA catheter - Cardionovum; PrimusDCBLatest Information Update: 15 Jan 2022
Price :
$50
*
At a glance
- Originator Cardionovum
- Class Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
- Mechanism of Action Immunosuppressants; Mitosis inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Coronary artery restenosis; Peripheral artery restenosis
Most Recent Events
- 24 Sep 2012 Efficacy and adverse events data from a clinical trial and pharmacodynamic data from a preclinical trial in Coronary artery restenosis released by Cardionovum
- 31 Mar 2012 Launched for Peripheral artery restenosis in Europe (Intra-arterial)
- 31 Mar 2012 Launched for Coronary artery restenosis in Europe (Intra-arterial)